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 BACKGROUND:  Few studies have prospectively reported outcomes in patients with pulmonary 
arterial hypertension (PAH) treated with epoprostenol in the modern-day era of oral therapy 
and combination treatments. Th e Registry to Prospectively Describe Use of Epoprostenol for 
Injection (Veletri, prolonged room temperature stable-epoprostenol [RTS-Epo]) in Patients 
with Pulmonary Arterial Hypertension (PROSPECT) was established to prospectively describe 
the course of PAH in patients prescribed RTS-Epo. 
 METHODS:  PROSPECT is a multicenter, US-based drug registry of primarily group 1 patients 
with PAH treated with RTS-Epo who were parenteral-naive or parenteral-transitioned at 
enrollment. Patients were followed until discontinuation of RTS-Epo, withdrawal, loss to 
follow-up, death, or end of study (maximum 1 year). One-year freedom from hospitaliza-
tion (FH) and survival estimates were summarized by prostacyclin history (parenteral-naive 
or parenteral-transitioned), sex, and chronic renal insuffi  ciency (CRI). 
 RESULTS:  A total of 336 patients were included. The overall 1-year FH estimate was 
51.0%   2.8% and was lower in parenteral-naive patients than parenteral-transitioned patients 
(42.8%   4.3% vs 57.1%   3.7%, respectively;  P  5 .002). FH estimates were lower in male 
patients than female patients (38.3%   5.9% vs 54.6%   3.2%, respectively;  P  , .015) and in 
patients with CRI than patients without CRI (17.0%    8.4% vs 53.7%   2.9%, respectively; 
 P  , .001). The overall 1-year survival estimate was 84.0%   2.1%. Survival was poorer in 
parenteral-naive patients, male patients, and patients with CRI. 
 CONCLUSIONS:  Risk of hospitalization and mortality remain high in patients with PAH. In 
particular, patients who are parenteral-naive at initiation of RTS-Epo therapy, male patients, 
and patients with CRI require close monitoring and aggressive clinical management. 
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 ABBREVIATIONS:  6MWD  5 6-min walk distance; BSI  5 blood stream 
infection; CRI  5 chronic renal insufficiency; CTD  5 connective 
tissue disease; IPAH  5 idiopathic pulmonary arterial hypertension; 
NYHA FC  5 New York Heart Association functional class; PAH  5 
pulmonary arterial hypertension; PPH  5 primary pulmonary hyper-
tension; PROSPECT  5 Registry to Prospectively Describe Use of 
Epoprostenol for Injection (Veletri, prolonged room temperature 
stable-epoprostenol [RTS-Epo]) in Patients with Pulmonary Arterial 
Hypertension; REVEAL Registry  5 Registry to Evaluate Early and 
Long-Term Pulmonary Arterial Hypertension Disease Management 
Registry; RTS-Epo  5 room temperature stable-epoprostenol; WHO  5 
World Health Organization  
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 Materials and Methods 
 Registry Design and Participants 
 Participants were enrolled between September 2010 and January 2012 
at 50 PAH centers across the United States, all of which received 
institutional review board approval. Patients were eligible if they had 
been diagnosed with PAH (group 1 pulmonary hypertension) and were 
parenteral-naive or parenteral-transitioned from another formulation 
of epoprostenol or treprostinil therapy to RTS-Epo. Patients were 
followed for a maximum of 1 year or until discontinuation of RTS-Epo, 
withdrawal of consent, loss to follow-up, death, or end of study. 
 Data Collection 
 Patient data were collected at enrollment and quarterly intervals 
(months 3, 6, 9, and 12) ( e-Table 1 ). No treatments or assessments were 
mandated by the protocol. Clinical characteristics, medical history, and 
comorbid conditions, including pulmonary function tests, echocardio-
gram, New York Heart Association functional class (NYHA FC) evalu-
ation, and 6-min walk distance (6MWD) were collected using the most 
recent clinical visits, hospitalization, and/or telephone contacts. Th e 
treating physician determined renal insuffi  ciency by selecting a check-
box in the electronic case report form. Among those patients who had a 
creatinine recorded, estimated glomerular fi ltration rate was computed. 
Dosing regimen and titration schedule for RTS-Epo and concomitant 
PAH medications were also collected quarterly. 
 Outcomes 
 Clinical outcomes from PROSPECT included demographics and 
disease characteristics of patients receiving RTS-Epo. Safety outcomes 
included all-cause deaths and hospitalizations and blood stream infec-
tions (BSIs). All outcomes were stratifi ed by patient demographics and 
disease characteristics. Hospitalizations were assigned by the treat-
ing physician as related to the use of RTS-Epo, due to PAH, both, or 
neither. Reports of BSIs leading to hospitalization or death were also 
collected. Hospitalizations for initiation of RTS-Epo were not collected. 
Hospitalizations were coded using the MedDRA coding dictionary 
(version 14.0). 
 Deaths were collected during the course of the study. Patients who 
discontinued the study for any reason were censored on the date of 
discontinuation. 
 Statistical Analysis 
 Baseline demographic and clinical characteristics were summ-
arized using percentages for categorical variables and means   SD for 
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 Pulmonary arterial hypertension (PAH) is a rare, progres-
sive disease characterized by increasing pulmonary 
vascular resistance and pressures, resulting in right-side 
heart failure, dyspnea, and decreasing functional status. 1 
Untreated, the median survival time in idiopathic pulmo-
nary arterial hypertension (IPAH) is 2.8 years, with esti-
mated survival rates of 68% at 1 year, 48% at 3 years, and 
34% at 5 years. 2 While outcomes have improved with 
the advent of new therapies, further progress is needed. 
In Th e Registry to Evaluate Early and Long-Term 
Pulmonary Arterial Hypertension Disease Management 
(REVEAL Registry), the 1-year, 3-year, 5-year, and 
7-year survival rates from time of diagnostic right-sided 
heart catheterization in a more diverse group of patients 
with PAH were 85%, 68%, 57%, and 49%, respectively. 3 
 Hospitalization has been suggested as an indicator of poor 
survival; death, lung transplantation, and hospitalization 
have been identifi ed as clinical effi  cacy measures in PAH 
clinical research. 4 Additionally, in a study evaluating defi -
nitions of clinical worsening as a predictor of proximate 
(within 1 year) risk for subsequent major events (ie, death, 
transplantation, or atrial septostomy), hospitalization was 
independently associated with poor survival: the 1-year 
survival rate in patients hospitalized was only 71.4%   1.5%. 5 
 Epoprostenol is an IV synthetic prostacyclin shown to 
improve exercise capacity and World Health Organization 
(WHO) functional class, while prolonging survival. 1,6-9 
Epoprostenol remains the recommended treatment of 
the most advanced cases of PAH. 10 Th ere are limited 
data documenting the long-term rates of hospitalization 
and survival beyond 12 weeks with epoprostenol. Prior 
studies of survival in patients on epoprostenol have been 
limited to patients with primary pulmonary hyperten-
sion (PPH, now known as IPAH) in an era where pros-
tacyclins were the only available therapy, and are limited 
to single-center cohort studies. 1,8,9,11 
 Epoprostenol for injection (Veletri, prolonged room 
temperature stable-epoprostenol [RTS-Epo]) is a US Food 
and Drug Administration (FDA)-approved formulation 
of epoprostenol that has improved stability over the 
standard formulation of epoprostenol at room tempera-
ture. 12 Th e Registry to Prospectively Describe the Use of 
RTS-Epo in Patients with Pulmonary Arterial Hyperten-
sion (PROSPECT) is a multicenter, prospective, observa-
tional registry of patients who were prescribed RTS-Epo. 
Th e registry longitudinally describes the modern-day 
course of patients with PAH treated with epoprostenol 
(RTS-Epo), by evaluating a broad range of clinical and 
patient-reported outcomes for 1 year aft er enrollment. 
Th e objective of this analysis is to assess the baseline 
characteristics and the risk of hospitalization and mor-
tality in this cohort. 
Open access under CC BY-NC-ND license. 
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 Results 
 Patient Demographic and Clinical Characteristics 
 A total of 354 patients enrolled in PROSPECT; 18 did 
not have PAH. Th us, the analytic cohort included the 
remaining 336 patients. Patient demographics and 
comorbid conditions at enrollment are summarized in 
 Table 1 . Th e clinical characteristics of all patients, and by 
prostacyclin history at enrollment, are summarized in 
 Table 2 . Patient characteristics at baseline by hospitaliza-
tion status, survival status (over 1 year of follow-up), 
and sex are summarized in  Table 3 . Th e most common 
reason for initiation to RTS-Epo was PAH progression 
in the parenteral-naive group (57.1%) and other in the 
parenteral-transitioned group (42.3%) ( e-Table 2 ). Among 
the 18 non-group 1 patients, chronic thromboembolic 
pulmonary hypertension and sarcoidosis each repre-
sented approximately one-third ( Table 4 ). Concomitant 
PAH medications at start of RTS-Epo in the non-group 
1 patients are summarized in  Table 2 . A summary of 
concomitant medications at enrollment for the patients 
in the non-WHO group 1 are summarized in Table 4. 
 Patients requiring hospitalization in the fi rst year were more 
likely to be men, have PAH associated with connective 
tissue disease (CTD), be NYHA FC III or IV, have a lower 
mean 6MWD, have a higher mean REVEAL Registry Risk 
Score, and were more likely to be parenteral prostanoid-
naive compared with patients who were not hospitalized. 
 Patients who died during the study were older, were more 
likely to have PAH associated with CTD, be NYHA FC IV, 
have a lower mean 6MWD, have a higher mean REVEAL 
Registry Risk Score, and were more likely to be parenteral 
prostanoid-naive compared with patients who survived. 
 Men comprised about 20% of the surviving patients in 
PROSPECT; 43.1% of the deaths occurred in men. Men 
were more likely than women to have familial PAH, 
congenital PAH, or PAH associated with portopulmonary 
hypertension. A higher mean REVEAL Registry Risk 
Score was observed in men, who were also more likely 
to be parenteral prostanoid-naive at enrollment compared 
with women. 
 Hospitalizations 
 A total of 296 on-study all-cause hospitalizations 
occurred in 157 patients (150 were parenteral-
naive patients and 146 were parenteral-transitioned 
 TABLE 1  ]  Patient Demographics and Comorbid 
Conditions at Enrollment (N  5 336) 
Demographics and Conditions Value
Age, y 50.0   14.6
Age groups, y
  , 18 6 (1.8)
 18-34 52 (15.5)
 35-44 56 (16.7)
 45-55 89 (26.5)
 56-64 75 (22.3)
   65 58 (17.3)
Female sex 258 (76.8)
Race
 White 251 (74.7)
 Black 31 (9.2)
 Hispanic 29 (8.6)
 Asian/Paciﬁ c Islander 15 (4.5)
 Unknown 7 (2.1)
 Other 3 (0.9)
Height in cm 164.2   10.2
Weight in kg 74.4   20.5
BMI, kg/m 2 27.4   6.4
Comorbid conditions, 10 most frequent
 Hypertension 112 (33.3)
 Obesity 82 (24.4)
 Hypothyroidism 66 (19.6)
 Scleroderma 58 (17.3)
 Diabetes 54 (16.1)
 Clinical depression 44 (13.1)
 Asthma 36 (10.7)
 COPD 32 (9.5)
 Renal insuﬃ  ciency 28 (8.3)
 None 24 (7.1)
 Data are given as mean   SD or No. (%). 
continuous variables. Th e REVEAL Risk Score calculator was included, 
which incorporates 19 variables that predict 1-year survival in 
patients with PAH. 13 Patient characteristics were summarized by 
hospitalization status (hospitalized vs not hospitalized), survival 
status (survived vs died), and sex. Rates of on-study hospitaliza-
tions (defined as those with a date of hospital admission after the 
date of enrollment) per 1,000 patient-days were calculated for all 
patients and by prostacyclin history (parenteral-naive or parenteral-
transitioned). 
 Survival over the 1 year of follow-up was estimated based on Kaplan-
Meier curves. For patients who died during follow-up, length of survival 
was calculated from the date of enrollment to the date of death reported. 
Patients who did not die were censored at the earlier of their date of 
discontinuation from the study or the date of the last data collection. 
Freedom from hospitalization, survival esti mates, and SEs were sum-
marized for all patients, and by prostacyclin history, sex, and chronic 
renal insuffi  ciency (CRI). Risk-adjusted hazard ratios were computed 
from a multivariable Cox regression model.  
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 TABLE 2  ]  Clinical Characteristics at Enrollment for All Patients and by Prostacyclin History 
Characteristics All Patients (N  5 336)
Parenteral-Naive 
(n  5 147) a 
Parenteral-Transitioned 
(n  5 189) b 
Specialty of diagnosing physician
 Pulmonologist 222 (66.1) 101 (68.7) 121 (64.0)
 Cardiologist 96 (28.6) 37 (25.2) 59 (31.2)
 Other 18 (5.4) 9 (6.1) 9 (4.8)
PAH duration in y 4.7   4.9 3.1   4.5 5.9   4.9
NYHA functional class at enrollment
 Class I 14 (4.2) 2 (1.4) 12 (6.3)
 Class II 85 (25.3) 24 (16.3) 61 (32.3)
 Class III 169 (50.3) 93 (63.3) 76 (40.2)
 Class IV 38 (11.3) 23 (15.6) 15 (7.9)
 Unknown 30 (8.9) 5 (3.4) 25 (13.2)
6MWD, m, mean   SD 334.6   128.0 308.2   113.4 350.5   133.8
Hemodynamic parameters
 RAP, mm Hg n  5 259 n  5 112 n  5 147
11.9   7.0 13.6   7.0 10.7   6.7
 mPAP, mm Hg n  5 275 n  5 123 n  5 152
52.9   14.3 54.8   13.1 51.4   15.1
 PCWP, mm Hg n  5 266 n  5 116 n  5 150
11.5   5.6 12.0   6.2 11.1   5.2
 Cardiac index, L/min/m 2 n  5 242 n  5 105 n  5 137
2.5   1.0 2.3   0.8 2.7   1.1
 Sv O 2 , % n  5 59 n  5 24 n  5 35
61.8   11.8 60.9   11.3 62.5   12.2
 PVRI, Wood units  3 m 2 n  5 225 n  5 99 n  5 126
19.7   12.3 21.7   12.0 18.0   12.4
Concomitant PAH medications, at RTS-Epo start
 PDE5i without ERA 82 (24.4) 32 (21.8) 50 (26.5)
 ERA without PDE5i 49 (14.6) 21 (14.3) 28 (14.8)
 PDE5i  1 ERA 81 (24.1) 37 (25.2) 44 (23.3)
 Neither 124 (36.9) 57 (38.8) 67 (35.4)
Initial dose of RTS-Epo c n  5 316 n  5 127 n  5 189
 Median 16.0 2.0 29.0
 Data are given as mean   SD or No. (%). 6MWD  5 6-min walk distance; ERA  5 endothelial receptor antagonist; mPAP  5 mean pulmonary arterial 
pressure; NYHA  5 New York Heart Association; PDE5i  5 type 5 phosphodiesterase inhibitor; PAH  5 pulmonary arterial hypertension; PCWP  5 pulmonary 
capillary wedge pressure; PVRI  5 pulmonary vascular resistance index (Wood units  3 m 2 ); RAP  5 right arterial pressure; RTS-Epo  5 room temperature 
stable-epoprostenol; Sv O 2  5 venous oxygen saturation. 
 a Includes n  5 119 patients who were prostacyclin-naive, n  5 26 patients who transitioned from an inhaled prostacyclin, and n  5 2 patients who 
transitioned from an oral prostacyclin at study entry. 
 b Includes n  5 180 patients who transitioned from epoprostenol and n  5 9 patients who transitioned from treprostinil at study entry. 
 c The initial dose at time of initiation of prolonged RTS-Epo, which may not be at enrollment. 
patients). The median length of stay was longer 
for parenteral-naive patients than for parenteral-
transitioned patients (median 5.0, interquartile 
range: 3.0, 9.0 vs median 4.0, interquartile range: 2.0, 
7.0, respectively). 
 Of the hospitalized patients (n  5 157), 77 (49.0%) 
were not rehospitalized, 51 (32.5%) were rehospi-
talized once, 12 (7.6%) were rehospitalized twice, 
and 17 (10.8%) were rehospitalized three or more 
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 TABLE 3  ]  Baseline Demographic and Clinical Characteristics Categorized by Hospitalization Status, Survival Status ( . 1 Y of Follow-up), and Sex 
Characteristics All Patients
Hospitalized Survived
Male FemaleYes No Yes No
Patients, No. 336 157 179 285 51 78 258
Age, y 50.0   14.6 50.7   14.6 49.4   14.7 49.5   14.7 52.8   14.3 49.0   14.7 50.3   14.6
Sex
 Male 78 (23.2) 44 (28.0) 34 (19.0) 56 (19.6) 22 (43.1) 78 (100) 0 (0)
 Female 258 (76.8) 113 (72.0) 145 (81.0) 229 (80.4) 29 (56.9) 0 (0) 258 (100)
Etiology
 IPAH 172 (51.2) 78 (49.7) 94 (52.5) 149 (52.3) 23 (45.1) 42 (53.8) 130 (50.4)
 HPAH 14 (4.2) 7 (4.5) 7 (3.9) 12 (4.2) 2 (3.9) 6 (7.7) 8 (3.1)
 Drugs/toxins 18 (5.4) 8 (5.1) 10 (5.6) 14 (4.9) 4 (7.8) 4 (5.1) 14 (5.4)
 APAH-CTD 91 (27.1) 47 (29.9) 44 (24.6) 75 (26.3) 16 (31.4) 8 (10.3) 83 (32.2)
 APAH-CHD 22 (6.5) 9 (5.7) 13 (7.3) 19 (6.7) 3 (5.9) 7 (9.0) 15 (5.8)
 APAH-PoPH 16 (4.8) 8 (5.1) 8 (4.5) 14 (4.9) 2 (3.9) 8 (10.3) 8 (3.1)
 APAH-HIV 2 (0.6) 0 (0.0) 2 (1.1) 1 (0.4) 1 (2.0) 2 (2.6) 0 (0.0)
 PPHN 1 (0.3) 0 (0.0) 1 (0.6) 1 (0.4) 0 (0.0) 1 (1.3) 0 (0.0)
NYHA FC
 Class I 14 (4.6) 7 (4.9) 7 (4.3) 14 (5.4) 0 (0.0) 2 (2.7) 12 (5.2)
 Class II 85 (27.8) 27 (18.8) 58 (35.8) 76 (29.5) 9 (18.8) 23 (30.7) 62 (26.8)
 Class III 169 (55.2) 88 (61.1) 81 (50.0) 145 (56.2) 24 (50.0) 39 (52.0) 130 (56.3)
 Class IV 38 (12.4) 22 (15.3) 16 (9.9) 23 (8.9) 15 (31.3) 11 (14.7) 27 (11.7)
6MWD, m 334.6   128.0 314.5   117.1 352.8   135.0 347.9   122.2 254.7   134.2 354.6   129.6 329.2   127.3
REVEAL Registry Risk Score 8.4   2.4 8.9   2.3 8.0   2.4 8.1   2.3 10.0   2.0 8.8   2.4 8.3   2.4
Parenteral-naive 147 (43.8) 79 (50.3) 68 (38.0) 118 (41.4) 29 (56.9) 48 (61.5) 99 (38.4)
Parenteral-transitioned 189 (56.3) 78 (49.7) 111 (62.0) 167 (58.6) 22 (43.1) 30 (38.5) 159 (61.6)
 Data are given as mean   SD or No. (%). APAH  5 associated pulmonary hypertension; CHD  5 congenital heart disease; CTD  5 connective tissue disease; HPAH  5 heritable pulmonary arterial hypertension; 
IPAH  5 idiopathic pulmonary arterial hypertension; PoPH  5 portopulmonary hypertension; PPHN  5 persistent pulmonary hypertension of the newborn; REVEAL Registry  5 Registry to Evaluate Early and Long-term 
Pulmonary Arterial Hypertension Disease Management. See  Table 2 legend for expansion of abbreviations. 
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 Figure 1 – Rates of on-study hospi-
talizations* (per 1,000 patient-d) in 
the PROSPECT cohort by prostacy-
clin history. *On-study hospitaliza-
tion defi ned as those with a date of 
hospital admission aft er the date of 
enrollment into PROSPECT. 
differences in frequencies of rehospitalization between 
parenteral-naive and parenteral-transitioned 
groups. 
 Rates and All Causes of Hospitalizations 
 The overall rate of all-cause hospitalizations in 
group 1 patients with PAH was 2.8 per 1,000 patient-days 
(3.3 per 1,000 patient-days in parenteral-naive patients 
and 2.4 per 1,000 patient-days in parenteral-transitioned 
patients [ Fig 1 ]). Hospitalization rates for the non-
group 1 patients was 2.0 per 1,000 patient-days. 
 All causes of hospitalization with at least fi ve occurrences 
are shown in  Table 5 . The most common causes of 
hospitalizations were infections (51) and heart fail-
ures (48). Th irty-seven percent of hospitalizations were 
categorized as being related to PAH (44% in the parenteral-
naive group and 31% in the parenteral-transitioned 
group). 
 A total of 21 BSIs (0.20 per 1,000 patient-days on study) 
developed in 16 patients, 19 of which resulted in hos-
pitalizations (10 in parenteral-naive patients [0.24 per 
1,000 patient-days] and nine in parenteral-transitioned 
patients [0.16 per 1,000 patient-days]). Of the 21 BSIs, 
15 were gram-positive (71.4%), three were gram-
negative (14.3%), and three were of unknown 
organism(s) (14.3%). Th ere were no hospitalizations 
related to BSIs in the non-group 1 patients. 
 Freedom From Hospitalization 
 Th e 1-year freedom from hospitalization estimate (  SE) 
for the n  5 336 group 1 patients was 51.0%   2.8%. Th e 
freedom from hospitalization estimate for patients who 
were parenteral-naive at enrollment was 42.8%   4.3% 
compared with 57.1%   3.7% for parenteral-transitioned 
patients ( P  5 .002) ( Fig 2A ). Th e freedom from hospital-
ization estimate for men was 38.3%   5.9%; for women, 
it was 54.6%   3.2% ( P  , .015) ( Fig 2B ). Patients with 




(N  5 18) a Parenteral-Naive (n  5 8)
Parenteral-Transitioned 
(n  5 10)
Concomitant PAH medications, at RTS-Epo start
 PDE5i without ERA 6 ( 33.3) 4 ( 50.0) 2 ( 20.0)
 ERA without PDE5i 2 ( 11.1) 0 ( 0.0) 2 ( 20.0)
 PDE5i  1 ERA 4 ( 22.2) 2 ( 25.0) 2 ( 20.0)
 Neither 6 ( 33.3) 2 ( 25.0) 4 ( 40.0)
 Data are given as No. (%). WHO  5 World Health Organization. See Table 2 legend for expansion of other abbreviations. 
 a Chronic thromboembolic pulmonary hypertension (5), sarcoidosis (6), carcinoid syndrome (1), pulmonary veno-occlusive disease/pulmonary capillary 
hemangiomatosis (1), lung disease (1), pulmonary hypoplasia, giant omphalocele (1), left-sided heart disease/morbid obesity (1), post-liver transplant 
pulmonary hypertension (1), and pulmonary hypertension due to underlying inﬂ  ammatory myopathy (1). 
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 TABLE 5  ]  All Causes of Hospitalizations a (With at 
Least Five Occurrences) in Patients During 
1 Y of Follow-up in PROSPECT 
Cause
Total Count, 
Absolute No. of 
Hospitalizations
Infections-pathogen unspeciﬁ ed b 51
Heart failures 48
Respiratory disorders (NEC) 17
Pulmonary vascular disorders 15
Electrolyte and ﬂ uid balance conditions 14
Gastrointestinal signs and symptoms 12
Cardiac arrhythmias 11
Bacterial infectious disorders 10
GI hemorrhages (NEC) 10
Anemias nonhemolytic and marrow 
depression
8
Complications associated with device 8
General system disorders (NEC) 8
Renal disorders (excluding 
nephropathies)
8
Decreased and nonspeciﬁ c blood 
pressure disorders and shock
5
Neurologic disorders (NEC) 5
Other causes c 73
Total d 296
 HLGT  5 high-level group term; HLT  5 high-level term; NEC  5 not 
elsewhere classiﬁ ed. See  Table 3 legend for expansion of other 
abbreviations. 
 a Hospitalizations were coded using the MedDRA coding dictionary based 
on HLGT, with additional detail provided from the HLT for the most 
common HLGTs. 
 b Includes 19 hospitalizations due to blood stream infections. 
 c Other causes include: cardiac therapeutic procedures (4); device 
issues (4); respiratory tract therapeutic procedures (4); bone and 
joint injuries (3); bronchial disorders (excluding neoplasms) (3); 
diabetic complications (3); investigations, imaging, and histopathology 
procedures (NEC) (3); pericardial disorders (3); viral infectious disorders (3); 
anal and rectal conditions (NEC) (2); body temperature conditions (2); 
cardiac disorder signs and symptoms (2); endocrine gland therapeutic 
procedures (2); exocrine pancreas conditions (2); hepatic and 
hepatobiliary disorders (2); joint disorders (2); medication errors (2); 
therapeutic procedures and supportive care (NEC) (2); cardiac and 
vascular investigations (excluding enzyme tests) (1); central nervous 
system vascular disorders (1); chemical injury and poisoning (1); 
CTDs (excluding congenital) (1); coronary artery disorders (1); epidermal 
and dermal conditions (1); GI conditions (NEC) (1); GI inﬂ ammatory 
conditions (1); GI motility and defecation conditions (1); GI neoplasms, 
malignant and unspeciﬁ ed (1); headaches (1); hepatobiliary investigations (1); 
hepatobiliary therapeutic procedures (1); lymphomas, non-Hodgkin’s 
unspeciﬁ ed histology (1); musculoskeletal and CTDs (NEC) (1); obstetric 
and gynecologic therapeutic procedures (1); parathyroid gland 
disorders (1); peritoneal and retroperitoneal conditions (1); platelet 
disorders (1); pleural disorders (1); Rickettsial infectious disorders (1); 
skin and subcutaneous tissue disorders (NEC) (1); therapeutic and 
nontherapeutic eﬀ ects (excluding toxicity) (1); thyroid gland disorders 
(1); upper respiratory tract disorders (excluding infections) (1). 
 d Seven patients with a hospitalization admission date on the same date 
as enrollment were excluded from the outcomes analysis. 
CRI had a lower freedom from hospitalization compared 
with patients without CRI (17.0%   8.4% vs 53.7%   2.9%; 
 P  , .001). 
 Survival Estimates 
 Th e 1-year survival estimate (  SE) for all patients in 
PROSPECT was 84.0%   2.1%. Th e 1-year survival 
estimate for patients who were classifi ed as parenteral-naive 
at baseline was lower than the survival estimate for 
patients who were parenteral-transitioned (79.4%   3.4% 
vs 87.7%   2.5%;  P  5 .038) ( Fig 3A ). Th e 1-year survival 
estimate in men was lower than in women (71.0%   5.2% 
vs 88.0%   2.1%;  P  , .001) ( Fig 3B ). A sensitivity analysis 
using an estimated glomerular fi ltration rate cutpoint 
rather than the qualitative defi nition of CRI produced 
similarly signifi cant results. A multivariate Cox regres-
sion model of group 1 patients confi rmed that sex and 
CRI were independent risk factors, whereas there was 
no diff erences between naive and transition patients 
aft er adjusting for diff erences in risk profi le. ( Table 6 ).
Th e 1-year survival estimate was lower than in patients 
without CRI (63.4%   9.3% vs 86.0%   2.0%;  P  , .001). 
Th e 1-year survival estimate in the non-group 1 patients 
was 88.9%   7.4%. 
 Discussion 
 PROSPECT is the fi rst modern-day registry, to our 
knowledge, to assess outcomes in a large series of 
patients with PAH taking epoprostenol and examine 
outcomes by prostacyclin history, risk of hospitaliza-
tion, and mortality in patients in a real-world setting. 
Th e strengths of the study include the size of the cohort, 
broad inclusion criteria, and 1-year follow-up. 
 Th is analysis shows a high burden of illness in these 
patients, with an overall 1-year probability of survival 
of 84%   2.1% and only about 50% remaining free of 
hospitalization at 1 year. Specifi c subgroups within 
PROSPECT were at higher risk of both hospitalization 
and mortality compared with their counterparts, in par-
ticular, patients who were parenteral-naive at enroll-
ment, male patients, and patients with CRI. Mean 
REVEAL Registry Risk Scores were higher in these 
subgroups, reconfi rming the applicability of the score 
to this patient population. 13 An interesting fi nding is 
the large proportion of hospitalizations due to various 
comorbid conditions which could be explained by patients 
with PAH living longer and developing unrelated or 
unrecognized complications of PAH. 
 Survival in patients with PAH in the modern treatment 
era has improved compared with previously observed 
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 Figure 2 – A, B, Freedom from hos-
pitalization at 1 y by prostacyclin 
history (A) and sex (B). 
survival. However, as outcomes among PAH subpopu-
lations vary substantially, 14 continuing rigorous disease 
management of PAH is important. Patient survival 
appears to be related to the ability of the right ventricle 
to adapt to the chronically elevated pulmonary artery 
pressure. 8 Hospitalizations have been recognized as not 
only an important outcome measure when assessing 
clinical effi  cacy in PAH trials, but also an important 
prognostic factor in patients with PAH. 4,5 While 
PROSPECT confirms that use of RTS-Epo is associ-
ated with greater survival rates than that historically 
expected, rates of hospitalization are still high for 
patients with the disease. Overall survival of patients 
taking RTS-Epo was comparable to other studies of 
epoprostenol. 1,8,9 However, these older studies were 
limited single-site studies of patients with PPH and 
did not include higher-risk patients from associated 
PAH subgroups. 
 Survival in patients with PPH treated with epoprostenol 
depends on disease severity. 9 In PROSPECT, patients 
who were parenteral-naive at baseline had worse 
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 Figure 3 – A, B, One-y survival by 
prostacyclin history (A) and sex (B). 
outcomes compared with patients who were parenteral-
transitioned. Th ese results support fi ndings that earlier 
initiation of prostacyclin therapy or more aggressive 
therapy should be considered. 15 A study found that 
treatment with oral therapy or parenteral prostacyclin 
as initial strategy was associated with a high survival 
rate in patients who were WHO functional class III 
and whose PAH was idiopathic, familial, or anorexigen 
associated. 16 Th e authors suggest that the more potent 
prostacyclins be reserved for high-risk patients, such as 
those with evidence of disease progression or those 
with treatment failure. It should be noted that fi ndings 
in this analysis may refl ect survivor bias in those already 
on parenteral therapy or the more critical nature of the 
disease in patients who are parenteral-naive. 
 Sex diff erences observed in this analysis are consistent 
with other studies. Although the incidence of PAH is 
higher in women, survival is lower in men. Th e 5-year 
survival rate from diagnosis in the REVEAL Registry 
was 52% in men compared with 62% in women. 17 It is 
unclear why women have a better survival rate than 
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 TABLE 6  ]  Multivariable Predictors of Mortality 
Predictors
Hazard 
Ratio 95% CI  P Value a 
NYHA/WHO FC IV 2.88 (1.53, 5.42) .001
Renal insuﬃ  ciency 2.64 (1.31, 5.32) .007
Male 3.03 (1.68, 5.50)  , .001
High BNP,  . 180 pg/mL 
or NT  . 1,500 pg/mL
2.04 (1.16, 3.59) .014
Low 6MWD,  , 165 m 2.29 (1.01, 5.16) .047
Prostacyclin-naive 1.21 (0.68, 2.14) .52
 BNP  5 b-type natriuretic peptide; NT  5 N-terminal pro b-type natriuretic 
pepetide. See  Table 2 and  4 legends for expansion of other 
abbreviations. 
 a A parameter for prostacylin-naive vs transitioned was forced in the 
model.  P  , .05 required for model inclusion for all other variables. 
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 BSIs are a critical concern and major contributor to 
hospitalizations in patients with PAH receiving parenteral 
therapy. Th e rate of BSIs observed in PROSPECT was 
0.20 per 1,000 patient-days, which is consistent with 
prior studies of BSIs in epoprostenol-treated patients. 23,24 
In a retrospective cohort study from the Centers for Disease 
Control, the rate of BSIs was 0.42 BSIs per 1,000 treatment-
days for patients on IV epoprostenol. 23 In the REVEAL 
Registry, the rate of BSIs for IV epoprostenol was 
0.12 per 1,000 treatment-days. 24 
 PROSPECT is subject to the inherent limitations of 
uncontrolled, observational studies for data acquisi-
tion and interpretation. Other limitations include the 
collection of hospitalization data, which was based on 
primary discharge diagnosis, and the broader catego-
rization of causes of hospitalization, which removed 
some granularity in the data. PROSPECT patients 
were not at risk for on-study events until enrollment. 
Although treatment initiation was proximate to 
enrollment for many patients, some survival bias 
likely exists. 25 Therefore, these results cannot be gen-
eralized directly to newly treated or newly diagnosed 
patients. 
 Conclusions 
 Risk of hospitalization and mortality remain high in 
patients with PAH. Patients who are parenteral-naive at 
initiation of RTS-Epo therapy, male patients, and 
patients with CRI require close monitoring and aggres-
sive clinical management. 
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